Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global helicobacter pylori infections treatment market is expected to surpass an impressive valuation of US$ 638.3 Million in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 7.04% from 2023 to 2033, reaching US$ 1,260 Million.
Helicobacter pylori (H. pylori) is a gram-negative aerobic bacterium that is frequently found in the stomach. While it helps to maintain the stomach ecology, it can also induce infections of the stomach lining. The bacteria can be one of the causes of stomach cancer, peptic ulcers, gastritis, small intestine contagion, and peptic ulcer disease. This has heightened the need for H. pylori infection diagnostic techniques.
The dispersion of such infections can be linked to a variety of aspects, along with a lack of adequate water supply, poor sanitation, a high population, and poor personal hygiene. Increased awareness of H. pylori infections in the cohort is one of the variables affecting the Helicobacter pylori diagnostics market's expansion. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
Report Attribute |
Details |
Expected Market Value (2023) |
US$ 638.3 Million |
Anticipated Forecast Value (2033) |
US$ 1,260 Million |
Projected Growth Rate (2023 to 2033) |
7.04% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
COVID-19 is an unprecedented global public health crisis that has impacted nearly every marketplace, and the lengthy effects are expected to have an influence on the industry's expansion over the forecast period. Our continuing research expands our research framework to include underlying COVID-19 concerns and potential next steps.
Antibiotic availability and affordability in addition to shorter processing duration will increase antibiotic implementation and requirement for pre and post-surveillance tests. Moreover, rising H. pylori infection rates, the necessity for early diagnosis of symptoms, and technological innovations in diagnostic procedures are estimated to drive overall growth over the forecast period.
Soaring Infectious Disease Incidence Rates and Increased Awareness to propel growth
The growing incidence of communicable diseases and soaring public awareness about infections are the key causes of the industry. Tuberculosis, Chlamydia, gonorrhea, other sexually transmitted illnesses (STDs), stomach flu (gastroenteritis), and bladder infections represent the most prevalent infectious illnesses caused by viruses (UTIs).
For example, according to a research released in 2021 titled "The Global Prevalence of Peptic Ulcer in the World: A Systematic Review and Meta-analysis," the worldwide incidence of peptic ulcer was around 8.4% in 2021. Because helicobacter pylori diagnostics are widely accepted for infectious disease diagnosis, such occurrences indicate that the market is projected to expand at a substantial rate over the coming years.
Diagnostic cost-effectiveness and the necessity for personalized antibiotic therapy drive market expansion
The market is expanding due to increased diagnostic cost-effectiveness and the requirement for personalized antibiotic therapy. The accessibility of low-cost antibiotics and short processing durations are anticipated to boost antibiotic regimen implementation, which will benefit consumers for both pre-and post-monitoring tests.
Furthermore, a rise in the prevalence of Helicobacter pylori infection, higher demand for early recognition of symptoms, and advancements in diagnostic methods all contribute to the market's growth.
Diagnostic test restrictions limit growth in the economy
Diagnostic test constraints are predicted to be a significant impediment to the expansion of the Helicobacter pylori diagnostics market. Serology-based assays, for example, have low sensitivity and specificity because they cannot distinguish between acute illness and IgG antibodies present after treatment.
North American Market Growth is credited to rising transmissible diseases
Over the projected timeframe, North America is likely to dominate the global helicobacter pylori diagnostics industry. The rise is attributed to aspects such as a rise in the instances of transmissible diseases, increased awareness of infectious diseases, and the introduction of new products.
For example, Biomerica Inc. announced in June 2021 that it had signed an exclusive five-year partnership deal with a Canadian partner for the marketing and sale of Biomerica's new and proprietary Helicobacter pylori test, hp+detect. The hp+detect product was created to identify and supervise helicobacter pylori infection, which is the major cause of stomach and duodenal ulcers and a health risk for gastric cancer.
As a result, such occurrences are expected to propel market expansion in the region. The gender representation of H. pylori infection indicates a male predominance worldwide, with an estimated 62,500,000 male and approximately 56,900,000 female cases in the United States in 2021.
Europe is estimated to have the second-highest volume of H. pylori sales
Europe is expected to possess the second-largest H. pylori sales volume, with 30% revenue by 2022. The extensive use of antibiotics in several countries is an important factor. Furthermore, rising investments and the emergence of different major influencers are being assessed as potential drivers of market growth.
The European Helicobacter Pylori Infections Treatment market is forecast to be the second biggest. The growing number of patients seeking an early diagnosis of helicobacter pylori infection in order to avoid peptic ulcers is predicted to boost the market growth in the European region.
Based on the National Institute for Health Research, Helicobacter pylori is prevalent in most nations, along with North European communities, in which an estimated one-third of grownups are still contaminated, meanwhile, the incidence is higher than 50% in South America, Asia, and south and east Europe. Moreover, Helicobacter pylori are still prominent in immigrants from Helicobacter pylori-endemic European countries. These aspects are predicted to propel the global helicobacter pylori testing market in Europe forward.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The diagnostic laboratories segment to grow at the fastest pace
During the forecast period, the diagnostic laboratories segment is anticipated to expand at the fastest rate. The primary reasons for healthy growth are more specialized and effective infection identification, along with greater awareness of infectious diseases.
In regards to revenue, the hospitals and diagnostics laboratories segments were responsible for more than 82% of the industry in 2022.
HDDT (high-dose dual therapy) segment to Grow Rapidly
Bismuth quadruple therapy (BQT) is currently widely used to eliminate H pylori. High-dose dual therapy (HDDT) is an effective alternative diagnosis.
As per the latest analysis, both BQT and HDDT can achieve comparable elimination rates and adherence, with HDDT causing fewer side effects in general. As a result, these segments are expected to witness major market growth.
The growing number of start-ups in the Helicobacter Pylori Infections Treatment market has increased product quality and worldwide sales. Furthermore, in order to gain a competitive edge, new start-ups are operating on recent developments and releasing new products such as:
Key players in the helicobacter pylori infections treatment market are Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM-H. pylori.
Report Attribute |
Details |
Market Value in 2023 |
US$ 638.3 Million |
Market Value in 2033 |
US$ 1,260 Million |
Growth Rate |
CAGR of 7.04% from 2023 to 2033 |
Base Year for Estimation |
2022 |
Historical Data |
2018 to 2022 |
Forecast Period |
2023 to 2033 |
Quantitative Units |
Revenue in US$ Million and CAGR from 2023 to 2033 |
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization |
Available Upon Request |
FMI projects the global Helicobacter Pylori Infections Treatment market to expand at a 7.04% value CAGR by 2033.
The global Helicobacter Pylori Infections Treatment market is estimated at a market value of US$ 638.3 Million.
The global Helicobacter Pylori Infections Treatment market is expected to garner a market value of US$ 1,260 Million.
FMI has projected North America to be one of the key regions for the Helicobacter Pylori Infections Treatment market.
Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM-H.pylori.
1. Executive Summary | Helicobacter Pylori Infections Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Bismuth-quadruple Therapy 5.3.2. Concomitant Therapy 5.3.3. Levofloxacin Triple Therapy 5.3.4. Bismuth Therapy 5.3.5. High-dose Dual Therapy 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Hospitals 6.3.2. Diagnostics Laboratories 6.3.3. Clinics 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East & Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The US 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By Application 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By Application 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By Application 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Application 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. The UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment 10.2.3. By Application 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Application 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Singapore 11.2.1.5. Thailand 11.2.1.6. Indonesia 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia Pacific 11.2.2. By Treatment 11.2.3. By Application 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Application 11.4. Key Takeaways 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Treatment 12.2.3. By Application 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Application 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. The US. 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2022 13.1.2.1. By Treatment 13.1.2.2. By Application 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2022 13.2.2.1. By Treatment 13.2.2.2. By Application 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2022 13.3.2.1. By Treatment 13.3.2.2. By Application 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2022 13.4.2.1. By Treatment 13.4.2.2. By Application 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2022 13.5.2.1. By Treatment 13.5.2.2. By Application 13.6. The UK 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2022 13.6.2.1. By Treatment 13.6.2.2. By Application 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2022 13.7.2.1. By Treatment 13.7.2.2. By Application 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2022 13.8.2.1. By Treatment 13.8.2.2. By Application 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2022 13.9.2.1. By Treatment 13.9.2.2. By Application 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2022 13.10.2.1. By Treatment 13.10.2.2. By Application 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2022 13.11.2.1. By Treatment 13.11.2.2. By Application 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2022 13.12.2.1. By Treatment 13.12.2.2. By Application 13.13. Singapore 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2022 13.13.2.1. By Treatment 13.13.2.2. By Application 13.14. Thailand 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2022 13.14.2.1. By Treatment 13.14.2.2. By Application 13.15. Indonesia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2022 13.15.2.1. By Treatment 13.15.2.2. By Application 13.16. Australia 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2022 13.16.2.1. By Treatment 13.16.2.2. By Application 13.17. New Zealand 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2022 13.17.2.1. By Treatment 13.17.2.2. By Application 13.18. GCC Countries 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2022 13.18.2.1. By Treatment 13.18.2.2. By Application 13.19. South Africa 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2022 13.19.2.1. By Treatment 13.19.2.2. By Application 13.20. Israel 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2022 13.20.2.1. By Treatment 13.20.2.2. By Application 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Treatment 14.3.3. By Application 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Phathom Pharmaceuticals 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Redhill Biopharma 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Takeda Pharmaceutical 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. AbbVie 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Cumberland Pharmaceuticals 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Eisai Co 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Bio-Rad Laboratories 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. F. Hoffmann-La Roche 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Alpha Laboratories 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Biohit 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 18: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 14: Global Market Attractiveness by Application, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by Application, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 29: North America Market Attractiveness by Application, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by Application, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by Application, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 59: Europe Market Attractiveness by Application, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033 Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033 Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033 Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 77: MEA Market Value (US$ Million) by Application, 2023 to 2033 Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 85: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 89: MEA Market Attractiveness by Application, 2023 to 2033 Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports